Global Cephalosporin Drugs Market 2015-2019

PART 01: Executive summary
Highlights 
PART 02: Scope of  the report
Market overview 
Top-vendor offerings 
PART 03: Market research methodology
Research methodology 
Economic indicators 
PART 04: Introduction
Key market highlights 
PART 05: Cephalosporin overview
Introduction 
Precursors of cephalosporins 
Mechanism of action 
General principles for the use of antibiotics 
Clinical uses 
Epidemiology 
PART 06: Overview on the consumption of antibiotics
Latin America 
Europe 
APAC 
PART 07: Legislation relating to antibiotic use in the US
PART 08: Market landscape
Market Overview 
Market size and forecast 
Five forces analysis 
PART 09: Market segmentation by generation of cephalosporin
First generation cephalosporins 
Second generation cephalosporins 
Third generation cephalosporins 
Fourth generation cephalosporins 
Fifth generation cephalosporins 
PART 10: Market segmentation by route of administration
Injection 
Oral 
PART 11: Geographical segmentation
Segmentation of global cephalosporin drugs market by geography 
Cephalosporin drugs market in Americas 
Cephalosporin drugs market in EMEA 
Cephalosporin drugs market in APAC 
PART 12: Market drivers
Special regulatory designation for pipeline molecules 
Rise in prevalence of infectious diseases 
Increase in awareness 
PART 13: Impact of drivers
PART 14: Market challenges
Development of drug resistance 
High generic penetration 
Weak pipeline 
PART 15: Impact of drivers and challenges
PART 16: Market trends
Use of combination therapies 
Increase in mergers and acquisitions 
Increasing irrational use of cephalosporins 
PART 17: Vendor landscape
Competitive Scenario 
Market Share Analysis 2014 
Other prominent vendors 
PART 18: Key vendor analysis
Allergan 
Astellas 
BMS 
GSK 
Merck 
Pfizer 
Sandoz 
Teva Pharmaceuticals 
PART 19: Appendix
List of abbreviation